Literature DB >> 24021953

Intrapleural administration of gelatin-embedded, sustained-release basic fibroblast growth factor for the regeneration of emphysematous lungs in rats.

Mitsumasa Kawago1, Tatsuya Yoshimasu2, Yasuhiko Tabata3, Masaya Yamamoto3, Yoshimitsu Hirai2, Takahiro Kinoshita4, Yoshitaka Okamura2.   

Abstract

BACKGROUND: Intra-airway and intra-arterial administration of gelatin-embedded, sustained-release basic fibroblast growth factor has stimulated regeneration of emphysematous lungs in animal experiments, but these routes of administration may also cause harm. This study investigated the effectiveness of intrapleural administration of gelatin-embedded, sustained-release basic fibroblast growth factor. This animal experiment preceded our clinical trial of intrapleural administration of sustained-release basic fibroblast growth factor in patients with chronic obstructive pulmonary disease accompanied by pneumothorax.
METHODS: Pulmonary emphysema was induced in Sprague-Dawley rats using porcine elastase. Gelatin-embedded, sustained-release basic fibroblast growth factor was administered via the left pleural cavity. The rats were divided into a group that received gelatin-embedded, sustained-release basic fibroblast growth factor (FGF(+) group, n = 6), and a group that did not (FGF(-)group, n = 6). Animals were sacrificed after 14 days, and the results were evaluated by histologic examination.
RESULTS: In the FGF(+) group, the mean linear intercept value of the alveolar septa was significantly shorter on the treated side than on the untreated side (65.1 ± 7.0 vs 114.4 ± 7.5 μm; P = .0005). There was no significant difference in the mean linear intercept value between the treated and untreated sides in the FGF(-) group.
CONCLUSIONS: Intrapleural administration of sustained-release basic fibroblast growth factor induced lung regeneration in rats with elastase-induced pulmonary emphysema. Crown
Copyright © 2014. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24021953     DOI: 10.1016/j.jtcvs.2013.07.039

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

Review 1.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

2.  Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation.

Authors:  Hyun Young Koo; Lamis Mf El-Baz; StaceyL House; Sarah N Cilvik; Samuel J Dorry; Nahla M Shoukry; Mohamed L Salem; Hani S Hafez; Nickolai O Dulin; David M Ornitz; Robert D Guzy
Journal:  J Pathol       Date:  2018-07-05       Impact factor: 7.996

3.  Comparison between Variable and Conventional Volume-Controlled Ventilation on Cardiorespiratory Parameters in Experimental Emphysema.

Authors:  Isabela Henriques; Gisele A Padilha; Robert Huhle; Caio Wierzchon; Paulo J B Miranda; Isalira P Ramos; Nazareth Rocha; Fernanda F Cruz; Raquel S Santos; Milena V de Oliveira; Sergio A Souza; Regina C Goldenberg; Ronir R Luiz; Paolo Pelosi; Marcelo G de Abreu; Pedro L Silva; Patricia R M Rocco
Journal:  Front Physiol       Date:  2016-06-30       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.